Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol is a typical (low-potency) antipsychotic of the thioxanthene class. Melitracen is a tricyclic antidepressant (TCA). This combination product is used for the treatment of anxiety and depression, particularly when these conditions coexist.
## Primary Indications
* Anxiety
* Depression
* Anxiety and depression with apathy or psychomotor retardation
## Adult Dosing
* **Typical starting dose:** 1 tablet (flupentixol 0.5 mg, melitracen 10 mg) twice daily.
* **Titration:** Dose can be increased based on individual patient response and tolerance.
* **Maximum dose:** 2 tablets three times daily (totaling flupentixol 3 mg, melitracen 30 mg daily). Doses higher than this are generally not recommended.
## Pediatric Dosing
* Data regarding the safety and efficacy of flupentixol and melitracen in pediatric populations are limited. Use is generally not recommended.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but lower doses and increased monitoring may be warranted due to potential for altered metabolism.
* **Renal Impairment:** No specific dose adjustments are established. Use with caution.
## Contraindications
* Hypersensitivity to flupentixol, melitracen, or other thioxanthenes/TCAs.
* Circulatory collapse, severe degrees of kidney or liver damage.
* Bone marrow depression.
* Untreated narrow-angle glaucoma.
* Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIs.
* Acute poisoning with alcohol, opioids, lithium, or antihistamines.
## Adverse Effects
* **Common:** Drowsiness, dry mouth, blurred vision, constipation, urinary retention, dizziness, headache, tremor, increased sweating.
* **Less Common/Serious:** Extrapyramidal symptoms (e.g., akathisia, dystonia, parkinsonism), cardiac arrhythmias, orthostatic hypotension, confusion, suicidal ideation, serotonin syndrome (especially with concomitant serotonergic drugs), neuroleptic malignant syndrome.
## Key Drug Interactions
* **MAOIs:** Risk of severe adverse reactions, including hypertensive crisis and serotonin syndrome. Avoid concomitant use.
* **CNS Depressants:** Alcohol, barbiturates, benzodiazepines can potentiate the sedative effects.
* **Anticholinergic Agents:** Increased risk of anticholinergic side effects.
* **Serotonergic Agents:** Increased risk of serotonin syndrome.
* **CYP2D6 Inhibitors:** May increase flupentixol and melitracen plasma concentrations.
* **QTc Prolonging Agents:** Additive risk of QTc interval prolongation and arrhythmias.
## Monitoring
* **Initial:** Assess for baseline mental status, cardiovascular status, and risk factors for adverse effects.
* **Ongoing:** Monitor for therapeutic response, adverse effects (especially sedation, anticholinergic effects, extrapyramidal symptoms, and cardiac changes if indicated), and potential for suicidal ideation.
* **Laboratory:** Routine laboratory monitoring is not typically required unless clinically indicated (e.g., LFTs in hepatic impairment, renal function).
## Clinical Pearls
* This combination aims to treat both anxiety and depressive symptoms.
* Due to the sedative properties, patients should be cautioned about operating machinery or driving until they know how the medication affects them.
* TCAs, including melitracen, have a narrow therapeutic index and can be cardiotoxic in overdose.
* Flupentixol can cause extrapyramidal symptoms; consider dose reduction or adjunctive treatment if they occur.
**Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Patients should always consult with their healthcare provider for any questions regarding their medication and treatment. Always verify current prescribing information with official drug compendia or product labeling.
